Skip to content
411 PRESS
Assorted pharmaceutical pills and tablets — representative photo for FDA drug recall

An assortment of pharmaceutical pills (representative file photo). Specific recalled product: see recall details below. Photo: Michael Nutt / Wikimedia Commons (CC BY-SA 2.0).

Recall Database

Drug & Medication Defects Recalls

This hub groups 361 records where the problem is a drug or medication defect — potency out of spec, a dosage or labeling error, a stability or dissolution failure, or a mix-up that puts the wrong strength in the package. Most are FDA drug records (337), with 24 CPSC records that involve a drug or medication product.

A drug defect is not always about the pill itself; a failed child-resistant closure or a mislabeled carton lands here too. If you take a prescription or over-the-counter medication that has been recalled, this is one of two hubs to check — the other is Drug & Medical Product Contamination, which covers impurity and sterility problems.

The notices span 2023–2026, heaviest in 2026. Every row links to the FDA or CPSC notice with the lot numbers and the recall reason.

361 recall records
Years 2023–2026
By agency FDA 337 · CPSC 24
Data through Jul 23, 2026

How this hub is built. This page groups the 361 recall records that 411 Press classifies as Drug & Medication Defects. Each record gets one primary hazard from a fixed, published rule set (taxonomy version 2026-07-28.C2.2 — this stamp marks when the classification rules last changed, not how current the recall data is; data currency is stated below). A record can carry secondary hazard tags but appears on only one hub. Regulators in this hub: FDA (337), CPSC (24). These notices were published 2023–2026. This is not an all-time archive — it is the current dataset, drawn from CPSC, FDA, and NHTSA notices and refreshed as new notices are ingested from the agency feeds, so it grows over time. A note on counting. This hub counts RECORDS, not recall events. The agencies package recalls differently — NHTSA issues one record per safety campaign, the CPSC one per recall, the FDA one per affected product line — so an FDA-heavy hub carries more product-line records per underlying recall than a CPSC or NHTSA one. Records here are grouped by hazard; the brand hubs, which rank companies, count by event instead. Every row links to the original agency notice. The agency's record is the authority; the hazard grouping is ours. For a small number of records the agency feed's own hazard text did not pass our integrity check; those rows read "See the agency notice for the hazard description" and link straight to the source, rather than show a summary we can't stand behind.

2026 (272)

  • FDAClass II

    Azelaic Acid Gel

    CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were received.

  • FDAClass II

    Dorzolamide HCl and Timolol Maleate Ophthalmic Solution

    Defective Container: Firm received multiple complaints of broken cap spikes and undeliverable drops.

  • FDAClass III

    Lidolog Kit

    Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan

  • FDAClass II

    Rohto Cooling Eye Drops Optic Glow (naphazoline hydrochloride 0.03%, povidone 0.5%, propylene glycol 0.2%)

    Lack of Assurance of Sterility

  • FDAClass II

    Rohto Cooling Eye Drops Max Strength (naphazoline hydrochloride 0.03%, polysorbate 80 0.2%)

    Lack of Assurance of Sterility

  • FDAClass II

    Rohto Cooling Eye Drops Max Strength (naphazoline hydrochloride 0.03%, polysorbate 90, 0.2%)

    Lack of Assurance of Sterility

  • FDAClass II

    Rohto Cooling Eye Drops Dry Aid (povidone 0.68%, propylene glycol 0.3%)

    Lack of Assurance of Sterility

  • FDAClass II

    Rohto Cooling Eye Drops Dry Aid (povidone 0.68%, propylene glycol 0.3%)

    Lack of Assurance of Sterility

  • FDAClass II

    Rohto Cooling Eye Drops Digi Eye (hypromellose 0.35%, tetrahydrozoline HCl 0.05%)

    Lack of Assurance of Sterility

  • FDAClass II

    Rohto Cooling Eye Drops Cool Relief (naphazoline hydrochloride 0.012%, polysorbate 80 0.2%)

    Lack of Assurance of Sterility

  • FDAClass II

    Rohto Cooling Eye Drops ALL-IN-ONE (hypromellose 0.2%, tetrahydrozoline HCL 0.05%, zinc sulfate 0.25%)

    Lack of Assurance of Sterility

  • FDAClass II

    Rising

    Presence of Precipitate: medication was crystallizing and particles floating in the bottle

  • FDAClass II

    Levothyroxine Sodium Tablets

    Subpotent Drug

  • FDAClass II

    Levothyroxine Sodium Tablets

    Subpotent Drug

  • FDAClass II

    Levothyroxine Sodium Tablets

    Subpotent Drug

  • FDAClass II

    Levothyroxine Sodium Tablets

    Subpotent Drug

  • FDAClass II

    Levothyroxine Sodium Tablets

    Subpotent Drug

  • FDAClass II

    Levothyroxine Sodium Tablets

    Subpotent Drug

  • FDAClass II

    Levothyroxine Sodium Tablets

    Subpotent Drug

  • FDAClass II

    Levothyroxine Sodium Tablets

    Subpotent Drug

  • FDAClass II

    Levothyroxine Sodium Tablets

    Subpotent Drug

  • FDAClass II

    Levothyroxine Sodium Tablets

    Subpotent Drug

  • FDAClass II

    Levothyroxine Sodium Tablets

    Subpotent Drug

  • FDAClass II

    Levothyroxine Sodium Tablets

    Subpotent Drug

  • FDAClass II

    BD ChloraPrep Clear

    Lack of Assurance of Sterility: Affected product may exhibit an open or incomplete seal on the packaging of the applicator

  • FDAClass II

    CLEVIPREX (clevidipine injectable emulsion) 50 mg/100 mL (0.5 mg/mL)

    Lack of Assurance of Sterility

  • CPSCCritical

    CVS Health Medicated Hemorrhoidal Wipes

    The recalled medicated wipes contain lidocaine, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The packaging of the wipes is not child-resistant, posing a risk of serious injury or death from poisoning if the contents of the wipes are ingested by young children.

  • FDAClass II

    Dextroamphetamine Saccharate

    Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules.

  • FDAClass II

    TopCare Health

    SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

  • FDAClass II

    QC Quality Choice, Carbamide Peroxide, 6.5%, 0.5 FL

    SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

  • FDAClass II

    meijer, Carbamide Peroxide 6.5%, 0.5 FL OZ (15 mL), Washer Bulb included, NDC 41250-835-33, DIST

    SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

  • FDAClass II

    LEADER

    SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

  • FDAClass II

    GOOD NEIGHBOR PHARMACY

    SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

  • FDAClass II

    Foster & Thrive

    SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

  • FDAClass II

    FAMILY Wellness

    SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

  • FDAClass II

    CVS Health

    SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

  • FDAClass II

    Clinere, Carbamide Peroxide, a) 2 bottles of Clinere Carbamide Peroxide (2 x 0.50 mL) 6.5%, 0.5 fl

    SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

  • FDAClass II

    CAREone

    SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

  • FDAClass II

    AUDIOLOGIST'S CHOICE

    SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

  • FDAClass II

    Pemetrexed for Injection 500mg/Vial

    Lack of Sterility Assurance

  • FDAClass II

    Pemetrexed for Injection 100mg/Vial

    Lack of Sterility Assurance

  • FDAClass II

    Bortezomib for Injection 3.5mg/Vial

    Lack of Sterility Assurance

  • FDAClass II

    Azacitidine for Injection 100mg/Vial

    Lack of Sterility Assurance

  • FDAClass II

    Nystatin Cream USP

    Subpotent Drug: Low out of specification assay results performed during long-term stability testing.

  • FDAClass II

    Glucagon Emergency Kit for Low Blood Sugar

    CGMP deviation: OOS result observed for the Gliding Force functionality test during 12-month long term stability testing.

  • FDAClass II

    Perampanel CIII Tablets

    Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.

  • FDAClass II

    Carton Label: MAJOR

    Subpotent Drug

  • FDAClass II

    Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets)

    CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.

  • FDAClass II

    ChloraPrep FREPP

    Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel

  • FDAClass II

    BD PurPrep

    Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel

  • FDAClass II

    BD ChloraPrep Scrub Teal

    Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel

  • FDAClass II

    BD ChloraPrep Scrub Teal

    Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel

  • FDAClass II

    BD ChloraPrep Hi-Lite Orange

    Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel

  • FDAClass II

    BD ChloraPrep Hi-Lite Orange

    Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel

  • FDAClass II

    BD ChloraPrep Hi-Lite Orange

    Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel

  • FDAClass II

    BD ChloraPrep CLear

    Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel

  • FDAClass II

    BD ChloraPrep CLear

    Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel

  • FDAClass II

    BD ChloraPrep Clear

    Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel

  • FDAClass II

    IMULDOSA

    Lack of assurance of Sterility:

  • FDAClass II

    Lidocaine HCl Injection USP

    Lack of Assurance of Sterility

  • FDAClass II

    Accucaine

    Lack of Assurance of Sterility

  • FDAClass II

    Levothyroxine Sodium Tablets

    Subpotent Drug

  • FDAClass II

    Povi-One

    sub potency

  • FDAClass II

    Sensipar (cinacalcet) Tablets

    CGMP Deviations

  • FDAClass II

    Sensipar (cinacalcet) Tablets

    CGMP Deviations

  • FDAClass II

    Sensipar (cinacalcet) Tablets

    CGMP Deviations

  • FDAClass II

    Rapidol

    CGMP Deviations; deficiencies observed during FDA inspection

  • FDAClass II

    Med Pride

    CGMP Deviations; deficiencies observed during FDA inspection

  • FDAClass II

    Med Pride

    CGMP Deviations; deficiencies observed during FDA inspection

  • FDAClass II

    Med Pride, HYDROCORTISONE CREAM 1%, Net Wt

    CGMP Deviations; deficiencies observed during FDA inspection

  • FDAClass II

    Med Pride, HYDROCORTISONE CREAM 1%, Net Wt

    CGMP Deviations; deficiencies observed during FDA inspection

  • FDAClass II

    Med Pride, 1% Clotrimazole Antifungal Cream, Net Wt

    CGMP Deviations; deficiencies observed during FDA inspection

  • FDAClass II

    Med Pride

    CGMP Deviations; deficiencies observed during FDA inspection

  • FDAClass II

    Med Pride

    CGMP Deviations; deficiencies observed during FDA inspection

  • FDAClass II

    Med Pride

    CGMP Deviations; deficiencies observed during FDA inspection

  • FDAClass II

    Lucky Super Soft

    CGMP Deviations; deficiencies observed during FDA inspection

  • FDAClass II

    Lucky Super Soft, Antifungal Athlete's Foot Cream, Clotrimazole 1% Cream, Net Wt

    CGMP Deviations; deficiencies observed during FDA inspection

  • FDAClass II

    Lil Drug Store

    CGMP Deviations; deficiencies observed during FDA inspection

  • FDAClass II

    Cura Hongos

    CGMP Deviations; deficiencies observed during FDA inspection

  • FDAClass II

    Circle K

    CGMP Deviations; deficiencies observed during FDA inspection

  • FDAClass III

    Focalin XR (dexmethylphenidate HCl) 5 mg

    Labeling: Incorrect or Missing Lot and/or Exp Date

  • FDAClass II

    Gasco Isopropyl Alcohol 70%, 32 oz (946 mL) Gasco Industrial Corp., PO Box 1360, Gurabo PR 00778, UPC 7 87302 12363 6

    Subpotent drug

  • FDAClass II

    Gasco Isopropyl Alcohol 70%

    Subpotent drug

  • FDAClass II

    Gasco Isopropyl Alcohol 70%, Net Contents: 16 Oz

    Subpotent drug

  • FDAClass II

    Drogueria San Juan Puerto Rico Isopropyl Alcohol 70%

    Subpotent drug

  • FDAClass II

    Drogueria San Juan Puerto Rico Isopropyl Alcohol 70%

    Subpotent drug

  • FDAClass II

    Drogueria San Juan Puerto Rico Isopropyl Alcohol 70%

    Subpotent drug

  • FDAClass I

    BD ChloraPrep FREPP Clear

    Non-Sterility: Due to presence of Aspergillus penicillioides. And Lack of Assurance of Sterility: Due to wrinkles in the paper lidding which may breach the seal area.

  • FDAClass II

    BD ChloraPrep FREPP Clear

    Lack of Assurance of Sterility: Due to wrinkles in the paper lidding which may breach the seal area.

  • FDAClass II

    BD ChloraPrep Clear

    Lack of Assurance of Sterility: Due to wrinkles in the paper lidding which may breach the seal area.

  • FDAClass I

    BD ChloraPrep Clear (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA))

    Non-Sterility: Due to presence of Aspergillus penicillioides.

  • FDAClass II

    Fenofibrate Capsules

    CGMP Deviations

  • FDAClass III

    Roast beef and cheddar closed face sandwich packed in clear plastic wrap with a green adhesive label

    Incorrect Product Label; Roast Beef and Swiss closed face sub sandwich labeled as Turkey and Cheddar closed face sub sandwich

  • FDAClass II

    Xyvona (levorphanol tartrate tablets)

    Labeling: Not Elsewhere Classified. This recall has been initiated in response to the denial by FDA of marketing the product under the proprietary name Xyvona

  • FDAClass II

    Xyvona (levorphanol tartrate tablets)

    Labeling: Not Elsewhere Classified. This recall has been initiated in response to the denial by FDA of marketing the product under the proprietary name Xyvona

  • FDAClass II

    safco SensiCaine-Ultra (20% Benzocaine), Topical Anesthetic Gel, Strawberry Flavor, 1 oz

    Defective container:may contain bottles with incomplete seals

  • FDAClass II

    Quala Dental Products

    Defective container:may contain bottles with incomplete seals

  • FDAClass II

    PureLife

    Defective container:may contain bottles with incomplete seals

  • FDAClass II

    Pearson Quality Topical Anesthetic Gel (20% Benzocaine)

    Defective container:may contain bottles with incomplete seals

  • FDAClass II

    DHP Topical Anesthetic Gel, Benzocaine 20%, Strawberry Flavor, 1 oz

    Defective container:may contain bottles with incomplete seals

  • FDAClass II

    Dental City TOPICAL ANESTHETIC GEL

    Defective container:may contain bottles with incomplete seals

  • FDAClass II

    Burkhart topical anesthetic gel

    Defective container:may contain bottles with incomplete seals

  • FDAClass II

    Clomiphene Citrate USP Active Pharmaceutical Ingredient (CAS : 50-41-9)

    cGMP deviations

  • FDAClass II

    PReye Vitamin See Antioxidant Preservative Free Eye Drops, Distributed by: PReye, LLC, Golden, CO

    Lack of Assurance of Sterility

  • FDAClass II

    Vasopressin 2 Units/2 mL in 0.9% Sodium Chloride, syringe, IntegraDose Compounding Services, LLC

    Subpotent Drug

  • FDAClass III

    Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL), 2 mL per Single-Dose Vial, Rx Only, Mfd

    Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan

  • FDAClass III

    PRED MILD

    Failed Stability Specifications

  • FDAClass II

    Great Value Hawaiian Roll 4pk, Item # F63384

    Firm observed oily and sticky substance on direct food contact surface packaging of finished product.

  • FDAClass II

    Lidocaine HCl Injection USP

    Lack of Assurance of Sterility

  • FDAClass II

    fentaNYL Citrate

    Subpotent Drug

  • FDAClass II

    Estradiol Gel

    Defective Container; packets were found to be either empty or partially full.

  • FDAClass II

    Gas-X, Simethicone 125 mg/ ANTIGAS, 120 SoftGels, Distributed by: Haleon, Warren, NJ 07059, UPC: 3 00674 35041 9

    Labeling: Not Elsewhere Classified- Incomplete inactive ingredient information on the carton labeling.

  • FDAClass II

    cimzia (certolizumab pegol)

    Lack of Assurance of Sterility

  • FDAClass II

    My Wife's Slaw Jalapeno Heat, packaged in 8 oz

    Product was manufactured and distributed without the benefit of an approved food establishment inspection and the required regulatory safety parameters could not be verified.

  • FDAClass II

    My Wife's Slaw, packaged in 8 oz

    Product was manufactured and distributed without the benefit of an approved food establishment inspection and the required regulatory safety parameters could not be verified.

  • FDAClass II

    Atomoxetine Capsules HCL

    Labeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg Capsule.

  • CPSCWarning

    Travel Size Afrin® Original Nasal Spray 6 mL Bottles

    The 6 mL nasal sprays contain an imidazoline, which must be in child-resistant packaging or meet the labeling requirements for non-complying packaging, as required by the Poison Prevention Packaging Act. The 6 mL nasal spray's packaging is not child-resistant nor bears the required labeling statement, posing a risk of serious injury or illness from poisoning, if the contents are swallowed by young children.

  • FDAClass II

    Oasis Tears PF

    Lack of Assurance of Sterility: The recall is being initiated out of an abundance of caution following FDA observations noted during a recent inspection of Excelvision.

  • FDAClass II

    Octreotide Acetate for Injectable Suspension

    Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

  • FDAClass II

    Similasan

    Lack of Assurance of Sterility: This recall has been initiated due to CGMP deviations found by the FDA during an inspection of the manufacturer.

  • FDAClass II

    iVIZIA

    Lack of Assurance of Sterility: This recall has been initiated due to CGMP deviations found by the FDA during an inspection of the manufacturer.

  • FDAClass II

    Systane

    Lack of Assurance of Sterility: Due to FDA inspection observations that it believes may impact product quality.

  • FDAClass II

    GenTeal Tears

    Lack of Assurance of Sterility: Due to FDA inspection observations that it believes may impact product quality.

  • FDAClass II

    Optase Dry Eye Intense Drops (Glycerin 0.2%)

    Lack of Assurance of Sterility

  • FDAClass II

    FRESHKOTE LUBRICANT EYEDROPS, Sterile, 0.33 FL OZ (10mL), Harrow Eye LLC, Nashville, TN USA

    Lack of Assurance of Sterility

  • FDAClass III

    Levocarnitine Injection

    Labeling: Missing Label

  • FDAClass III

    Premier

    Labeling: Incorrect or Missing Lot and/or Exp Date:The expiration date has an extra digit and is printed as 2709114 instead of the correct 270914 (2027-09-14). It is important to note that this error is limited to the vial itself; the saleable unit of the box of 12 bottles has the correct expiration date printed.

  • FDAClass III

    busPIRone Hydrochloride Tablets

    Subpotent drug

  • FDAClass II

    Omega-3-Acid

    Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.

  • CPSCCritical

    Various Brands of Iron-Containing Dietary Supplements

    The dietary supplements contain iron, which must be in child-resistant packaging as required by the Poison Prevention Packaging Act. The packaging of the supplements is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.

  • FDAClass II

    vite20 Antifungal Cream

    CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry

  • FDAClass II

    TRIPENICOL S Antifungal Solution (Undecylenic Acid 25%)

    CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry

  • FDAClass II

    TERPENICOL Antifungal Solution

    CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry

  • FDAClass II

    TERPENICOL Antifungal Cream (Undecylenic Acid 13%)

    CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry

  • FDAClass II

    Fungal Fusion ERADICATION Solution, Antifungal & Antimicrobial Kit

    CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry

  • FDAClass II

    Desmopressin Nasal Spray

    Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.

  • FDAClass III

    Lidocaine Wound Gel (Benzalkonium Chloride, 0.13% and Lidocaine Hydrochloride, 2%)

    Failed PH Specifications

  • FDAClass II

    Alendronate Sodium Oral Solution, 70 mg/75 mL, 75 mL, Rx only, 4 x 75 mL Single Dose Bottles, Distr

    This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side.

  • FDAClass II

    DELFLEX

    Lack of Assurance of Sterility: Potential leaks from perforations in bags.

  • FDAClass II

    DELFLEX

    Lack of Assurance of Sterility: Potential leaks from perforations in bags.

  • FDAClass II

    Lidocaine HCl Injection

    Lack of Assurance of Sterility

  • FDAClass II

    Lidocaine HCl injection

    Lack of Assurance of Sterility

  • FDAClass II

    Bupivacaine Hydrochloride 0.75% in 8.25% Dextrose Injection

    Lack of Assurance of Sterility

  • FDAClass II

    0.9% Sodium Chloride Injection

    Lack of Assurance of Sterility

  • FDAClass II

    Sterile Water for Injection USP, 3000 mL bags, Rx only, Pharmacy Bulk Package, B

    Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed.

  • FDAClass II

    LACTATED RINGER'S IRRIGATION, 3000 mL bags, Sterile, Ex only, B

    Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed.

  • FDAClass II

    DEXTROSE INJECTION USP, 70%, 2000 mL bags, Rx only, Sterile, B

    Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed.

  • FDAClass II

    0.9 % SODIUM CHLORIDE IRRIGATION, USP, 3000 mL bags, Rx only, Sterile, B

    Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed.

  • CPSCCritical

    TecFlox Hair and Beard Growth Serum Bottles

    The hair and beard growth serum contains minoxidil, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The bottles are not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.

  • CPSCCritical

    Tuymec Minoxidil Hair Growth Kits, 5% Minoxidil with Biotin Spray

    The hair serum contains minoxidil, which must be in child-resistant packaging as required by the Poison Prevention Packaging Act. The hair serum's packaging is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.

  • FDAClass II

    Phenylephrine Hydrochloride Injectable Solution, 40mg, 250*mL Bag, wells pharma of Houston, NDC 73702-122-03

    cGMP deviations.

  • FDAClass II

    Ketamine Hydrochloride Injectable Solution

    cGMP deviations.

  • FDAClass II

    fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 50 mcg/5mL)(10 mcg per mL), wells pharma, NDC 73702-202-15

    cGMP deviations.

  • FDAClass II

    fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride

    cGMP deviations.

  • FDAClass II

    fentaNYL Citrate injectable Solution in 0.9% Sodium Chloride

    cGMP deviations.

  • FDAClass II

    fentaNYL Citrate Injectable Solution

    cGMP deviations.

  • FDAClass II

    fentaNYL Citrate Injectable Solution

    cGMP deviations.

  • FDAClass II

    Label is predominantly green with white lettering in a clear plastic clamshell container

    mislabeled Coconut Date Bites. (product is coconut covered, label is for regular date bites)

  • FDAClass II

    EPINEPHRINE Injection, USP, 1 mg/10mL (0.1 mg/mL), Rx only, INTERNATIONAL MEDICATION SYSTEMS, LIMITED, So

    Lack of Assurance of Sterility

  • FDAClass II

    Blemish Spot Treatment (Salicylic Acid) 1%

    Failed Stability Specifications

  • FDAClass III

    Magnesium Chloride

    Subpotent drug

  • FDAClass II

    Fluocinonide

    Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.

  • FDAClass II

    Fluocinonide

    Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.

  • FDAClass II

    Fluocinonide

    Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.

  • FDAClass II

    Artificial Tears Lubricant Eye Drops (glycerin 0.2%, hypromellose 0.2%, polyethylene glycol 400 1%)

    Lack of Assurance of Sterility

  • FDAClass II

    Discount Drug Mart Food Market

    This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.

  • FDAClass II

    Discount Drug Mart Food Market

    This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.

  • FDAClass II

    Vancomycin HCL, 1 gram added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St

    Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

  • FDAClass II

    Vancomycin HCI, 1.5 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St

    Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

  • FDAClass II

    Vancomycin HCI, 1.25 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St

    Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

  • FDAClass II

    norepinephrine Bitartrate, 32mg per 250mL 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St

    Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

  • FDAClass II

    norepinephrine Bitartrate,16mg per 250mL 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St

    Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

  • FDAClass II

    Clonidine Transdermal System

    CGMP Deviations: use of an unapproved raw material

  • FDAClass II

    Clonidine Transdermal System

    CGMP Deviations: use of an unapproved raw material

  • FDAClass II

    Clonidine Transdermal System

    CGMP Deviations: use of an unapproved raw material

  • FDAClass III

    Skin Rehab, Calming Skin Gel, Hydrocortisone Balm, hydrocortisone 1%, .53oz net wt

    Subpotent Drug

  • FDAClass III

    Remedy Gel, hydrocortisone 1%, 30 mL/ 1 fl oz per bottle, Distributed By: glo Skin Beauty, Denver, CO 80216

    Subpotent Drug

  • FDAClass III

    Essential Calming Skin Gel, hydrocortisone 1%, 120mL/4oz net wt

    Subpotent Drug

  • FDAClass II

    Octreotide Acetate for Injectable Suspension

    Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

  • FDAClass II

    Octreotide Acetate for Injectable Suspension

    Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

  • FDAClass II

    Octreotide Acetate for Injectable Suspension

    Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

  • FDAClass II

    CUROSURF (poractant alfa)

    Lack of Assurance of Sterility

  • FDAClass III

    POPPING BOBA RTD STRAWBERRY DRAGON F/OOLONG TEA 12 X 13.8OZ

    Packaging integrity issue that may compromise product quality .

  • FDAClass III

    POPPING BOBA RTD PEACH OOLONG TEA 12 X 13.8OZ

    Packaging integrity issue that may compromise product quality .

  • FDAClass III

    POPPING BOBA RTD MIXED BERRY HIBISCUS TEA 12 X 13.8OZ

    Packaging integrity issue that may compromise product quality .

  • FDAClass III

    POPPING BOBA RTD MANGO PASSION FRUIT GREEN TEA 12 X 13.8OZ

    Packaging integrity issue that may compromise product quality .

  • FDAClass II

    Meclizine Hydrochloride Tablets

    Failed tablet specifications.

  • FDAClass II

    Lanreotide Injection

    Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

  • FDAClass II

    Lanreotide Injection

    Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

  • FDAClass II

    5% Dextrose Injection

    Lack of Assurance of Sterility

  • FDAClass II

    5% Dextrose Injection

    Lack of Assurance of Sterility

  • FDAClass II

    5% Dextrose Injection

    Lack of Assurance of Sterility

  • FDAClass II

    0.9% Sodium Chloride Injection

    Lack of Assurance of Sterility

  • FDAClass II

    0.9% Sodium Chloride Injection

    Lack of Assurance of Sterility

  • FDAClass II

    0.9% Sodium Chloride Injection

    Lack of Assurance of Sterility

  • FDAClass II

    0.9% Sodium Chloride Injection

    Lack of Assurance of Sterility

  • FDAClass II

    0.9% Sodium Chloride Injection

    Lack of Assurance of Sterility

  • FDAClass II

    0.9% Sodium Chloride Injection

    Lack of Assurance of Sterility

  • FDAClass II

    0.9% Sodium Chloride Injection

    Lack of Assurance of Sterility

  • FDAClass II

    0.9% Sodium Chloride Injection

    Lack of Assurance of Sterility

  • FDAClass II

    0.9% Sodium Chloride Injection

    Lack of Assurance of Sterility

  • FDAClass II

    0.9% Sodium Chloride Injection

    Lack of Assurance of Sterility

  • FDAClass II

    0.45% Sodium Chloride Injection

    Lack of Assurance of Sterility

  • FDAClass II

    Semaglutide-Glycine-Cyanocobalamin Injectable

    Lack of Assurance of Sterility

  • FDAClass II

    Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution 0.2%/0.5%*, 5 mL, Rx Only, Sterile, Apotex Corp

    Lack of Assurance of Sterility

  • CPSCCritical

    Tomum Hair Regrowth Treatment with Minoxidil for Men and Women Spray Bottles

    The hair serum contains minoxidil, which must be in child-resistant packaging as required by the Poison Prevention Packaging Act. The hair serum's bottles are not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.

  • FDAClass II

    Ultra Lubricating Eye Drops (polyethylene 400 0.4%, propylene glycol 0.3%)

    Lack of Assurance of Sterility

  • FDAClass II

    STERILE EYE DROPS SOOTHING TEARS (polyethylene glycol 400 0.4% and propylene glycol 0.3%)

    Lack of Assurance of Sterility

  • FDAClass II

    Sterile EYE DROPS REDNESS LUBRICANT (glycerin 0.25% and naphazoline HCl 0.012%)

    Lack of Assurance of Sterility

  • FDAClass II

    Sterile Eye Drops ORIGINAL FORMULA (tetrahydrozoline HCl 0.05%)

    Lack of Assurance of Sterility

  • FDAClass II

    Sterile EYE DROPS AC (tetrahydrozoline HCl 0.05%, zinc sulfate 0.25%), 0.5 fl

    Lack of Assurance of Sterility

  • FDAClass II

    EYE DROPS Advanced Relief

    Lack of Assurance of Sterility

  • FDAClass II

    Dry Eye Relief Eye Drops

    Lack of Assurance of Sterility

  • FDAClass II

    Artificial Tears Sterile Lubricant Eye Drops (polyvinyl alcohol 0.5%, povidone 0.6%)

    Lack of Assurance of Sterility

  • FDAClass II

    Tirzepatide Inj

    Lack of Assurance of Sterility

  • FDAClass II

    Tirzepatide Inj

    Lack of Assurance of Sterility

  • FDAClass II

    Semaglutide Inj

    Lack of Assurance of Sterility

  • FDAClass II

    Semaglutide Inj

    Lack of Assurance of Sterility

  • FDAClass II

    Levothyroxine Sodium Tablets USP 150 mcg

    Subpotent Drug

  • FDAClass III

    C2O Coconut Water with Pulp (17.5 oz) 15 Pack UPC: 8-50274-00792-8

    The outer cardboard box for the canned coconut water has the incorrect Nutrition Facts Panel and Ingredient List, which does not include added sugar (5g per 17.5oz can), while the primary packaging (the can) has the correct Nutrition Facts Panel and Ingredient List.

  • FDAClass III

    Gelatin Capsule Pack for use with the Sodium Iodide I-131 Kit

    Failed Tablet/Capsule Specifications

  • FDAClass II

    MAXIMUM

    Stability Data Does Not Support Expiry Date.

  • FDAClass II

    MAXIMUM, ZONE 1, 4% Lidocaine Cream, 1/2 oz bottles, Distributed By: Dermal Source, Portland, OR 97232, NDC 80069-014

    Stability Data Does Not Support Expiry Date.

  • FDAClass II

    FIVE-STAR

    Stability Data Does Not Support Expiry Date.

  • FDAClass III

    Nilotinib Capsules

    Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

  • FDAClass III

    Nilotinib Capsules

    Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

  • FDAClass II

    Midodrine Hydrochloride Tablets

    Defective container; inadequately sealed blister packaging.

  • FDAClass III

    Eptifibatide Injection

    Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.

  • FDAClass I

    Product label reads in part as "WHITE VEIN ADVANCED ALKALOIDS CHEWABLE TABLETS 225mg 7-Hydroxymitragynine per container

    A sample of the product revealed the active ingredient is in a quantity greater than the labeled specification.

  • FDAClass II

    Cetrorelix Acetate for Injection (Kit), 0.25 mg per vial, Single-Dose Kit, Rx Only, Mfd

    Defective Delivery System: Missing or duplicated needles within the injection kit

  • FDAClass II

    vancomycin HCl

    Lack of Assurance of Sterility

  • FDAClass II

    vancomycin HCl

    Lack of Assurance of Sterility

  • FDAClass II

    thiamine HCl

    Lack of Assurance of Sterility

  • FDAClass II

    ketamine HCl

    Lack of Assurance of Sterility

  • FDAClass II

    acyclovir sodium

    Lack of Assurance of Sterility

  • FDAClass II

    Pro Numb Tattoo Numbing Spray

    cGMP deviations

  • FDAClass II

    Pro Numb Tattoo Numbing Spray

    cGMP deviations

  • CPSCCritical

    Viofairy Hair Growth Serum

    The serum bottles contain minoxidil, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The serum's packaging is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.

  • CPSCCritical

    Sefudun Hair Growth Serum Kits

    The hair growth serum contains minoxidil, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The serum bottle is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.

  • CPSCCritical

    Ultimate Multivitamin+ Dietary Supplement Bottles

    The bottles are filled with dietary supplements containing iron, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The packaging is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.

  • FDAClass II

    Diclofenac Sodium, Topical Gel, 3%, 100 g tube, Rx only, Mfd

    Failed Viscosity Specifications: Out of Specification (OOS) [slightly lower than the limit] result in viscosity for Diclofenac Sodium Gel, 3%.

  • CPSCCritical

    Iristar Minoxidil Spray Bottles

    The recalled spray bottles contain minoxidil, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The packaging is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.

  • FDAClass II

    WP WipesPlus Hand Sanitizing Wipes (Benzalkonium Chloride 0.13%), 5x7, 100 CT, Progressive Products, 211 S

    CGMP Deviations

  • FDAClass II

    Wipes Plus

    CGMP Deviations

  • FDAClass II

    Savannah Antibacterial Towelettes (Benzalkonium Chloride 0.13%), 1 towelette, 4 x 7, R&R Enterprise, NDC 59647-749-02

    CGMP Deviations

  • FDAClass II

    Medi-First Antiseptic Wipes (BZK)(Benzalkonium Chloride 0.13%)

    CGMP Deviations

  • FDAClass II

    Med-Nap Cleansing Towelettes (Benzalkonium Chloride 0.13%)

    CGMP Deviations

  • FDAClass II

    Med Nap BZK Antiseptic Towelettes (Benzalkonium Chloride 0.13%)

    CGMP Deviations

  • FDAClass II

    Max Packaging Antibacterial Towelette (Benzalkonium Chloride 0.13%)

    CGMP Deviations

  • FDAClass II

    Hand Sanitizing Wipes (Benzalkonium Chloride 0.13%)

    CGMP Deviations

  • FDAClass II

    Green Guard Antiseptic Wipes (Benzalkonium Chloride 0.13%), 25 wipes per box, Distributed by Green Guard, St

    CGMP Deviations

  • FDAClass II

    First Aid Only BZK Antiseptic Towelettes (Benzalkonium Chloride 0.13%), 50 Wipes, NDC 0924-7116-03

    CGMP Deviations

  • FDAClass II

    First Aid Only BZK Antiseptic Towelettes (Benzalkonium Chloride 0.13%) 100 Wipes, NDC 0924-7116-04

    CGMP Deviations

  • FDAClass II

    First Aid Only BZK Antiseptic Towelette (Benzalkonium Chloride 0.13%)

    CGMP Deviations

  • FDAClass II

    Dynarex Obstetrical Towelettes Cleanser (Benzalkonium Chloride 0.13%)

    CGMP Deviations

  • FDAClass II

    Dynarex

    CGMP Deviations

  • FDAClass II

    Dynarex

    CGMP Deviations

  • FDAClass II

    Dukal BZK Antiseptic Towelette (Benzalkonium Chloride 0.13%) 1000 Packs per case

    CGMP Deviations

  • FDAClass II

    Cleansing Towelette (Benzalkonium Chloride 0.13%)

    CGMP Deviations

  • FDAClass II

    Children's Healthcare of Atlanta

    CGMP Deviations

  • FDAClass II

    BZK Antiseptic Towelettes (Benzalkonium Chloride 0.13%)

    CGMP Deviations

  • FDAClass II

    Antimicrobial Alcohol Hand Wipe

    CGMP Deviations

  • FDAClass II

    1) BZK Antiseptic Towelettes (Benzalkonium Chloride 0.13%) 5"x7" Piedmont Sanitizing Hand Wipes

    CGMP Deviations

  • FDAClass II

    Thyroid

    Subpotent Drug

  • FDAClass II

    methylprednisolone tablets

    Labeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil.

  • CPSCCritical

    Ruahouine Hair Growth Serum Bottles

    The serum bottles contain minoxidil, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The serum's packaging is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.

  • CPSCCritical

    RootStim Beard Growth Serum, 5% Minoxidil

    The beard growth serum contains minoxidil, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The serum's packaging is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.

  • FDAClass II

    spicely ORGANIC sumac NO ARTIFICIAL COLORING NO GLUTEN - NO MSG - NO SOY NO PRESERVATIVES - NO WHEAT NO SUGAR - NO SALT

    Product contains salt and is mislabeled

  • FDAClass II

    spicely ORGANIC garlic salt NO ARTIFICIAL COLORING NO GLUTEN - NO MSG - NO SOY NO PRESERVATIVES - NO WHEAT NO SUGAR

    Product contains salt and is mislabeled

  • FDAClass II

    spicely ORGANIC celery salt NO ARTIFICIAL COLORING NO GLUTEN - NO MSG - NO SOY NO PRESERVATIVES - NO WHEAT NO SUGAR

    Product contains salt and is mislabeled

  • FDAClass II

    Oxycodone Hydrochloride Tablets

    Defective container: card seal defects (weak/non-existent seals), leading to the tablets falling out of their cavities.

  • FDAClass II

    AQ 120 GFEW, Aquarion Preserved Cartridges (2) 3.7 Gallons each

    cGMP deviations.

2025 (87)

  • FDAClass II

    Vista Tears Polyethylene Glycol 400 0.4% w/v

    Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.

  • FDAClass II

    Vista Meibo Tears Propylene Glycol 0.6% w/v Eye Drops Advanced Dry Eye Relief Revitalizing Formula

    Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.

  • FDAClass II

    Vista Gonio Eye Lubricant, Hypromellose Ophthalmic Solution USP

    Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.

  • FDAClass II

    Vista Gel Hypromellose USP 0.3% w/v, Eye Drops Dry Eye Relief Lubricating Gel, 10 ml

    Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.

  • FDAClass II

    CHNaO Fluorescein Sodium Ophthalmic Strips

    Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.

  • FDAClass II

    BioGlo Fluorescein Sodium Ophthalmic Strips USP, 100 diagnostic strips, Manufactured by Omni Lens PVT

    Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.

  • FDAClass II

    Bio Glo Fluorescein Sodium Ophthalmic Strips USP

    Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.

  • FDAClass II

    Icosapent Ethyl capsules, 1 gram, 120-count bottles, Rx only, Manufactured by: Softgel Healthcare Pvt

    Subpotent Drug: Due to oxidation caused by leakage of the contents of the capsules

  • FDAClass II

    Ondansetron Orally Disintegrating Tablets

    Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.

  • FDAClass III

    parodontax (cetylpyridinium chloride)ACTIVE GUM HEALTH, Mouthwash, Mint

    Labeling: Incorrect or Missing Lot and/or Exp Date: Potential for missing or illegible lot and expiration date coding on the bottles.

  • FDAClass I

    Rheumacare capsules, 30 count bottle, Mfg in India by: Virgo UAP Pharma Pvt

    CGMP Deviations: product found to contain lead.

  • FDAClass III

    Diclofenac Sodium Topical Gel

    Failed PH Specifications

  • FDAClass III

    traZODONE Hydrochloride Tablets

    Failed Tablet/Capsule Specifications: Product complaint received that some tablets had a dent on the plain side of the tablet surface.

  • FDAClass II

    INON ACE Antacid tablets (magnesium aluminosilicate, magnesium hydroxide and simethicone)

    Failed Disintegration Specifications: above the time expected.

  • CPSCCritical

    Mamisan Pain Relieving Topical Ointment

    The ointment contains lidocaine, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The ointment's packaging is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.

  • CPSCCritical

    Feel The Beard Minoxidil Beard Growth Oil for Men

    The beard serum contains minoxidil, which must be in child-resistant packaging as required by the Poison Prevention Packaging Act. The hair serum's packaging is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.

  • FDAClass II

    Oxycodone and Acetaminophen CII Tablets USP

    Failed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets.

  • FDAClass II

    Oxycodone and Acetaminophen CII Tablets USP

    Failed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets.

  • FDAClass II

    ORL Kids Natural Toothpaste, Bubblegum Flavor, 4 oz (120ml), ORL Labs, LLC, Scottsdale, Arizona USA

    cGMP Deviations

  • FDAClass II

    ORL Kids Mouthwash, Bubblegum Flavor, 16.9 oz

    cGMP Deviations

  • FDAClass III

    Cisatracurium Besylate Injection USP

    Subpotent product:out of specification assay results observed during long term stability testing.

  • FDAClass III

    Cisatracurium Besylate Injection USP

    Subpotent product:out of specification assay results observed during long term stability testing.

  • FDAClass III

    Cisatracurium Besylate Injection USP

    Subpotent product:out of specification assay results observed during long term stability testing.

  • FDAClass II

    Ondansetron ODT Tablets

    Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.

  • FDAClass III

    Varenicline Tablets, 1mg, 56 Tablets, Rx only, Distributor: Dr

    Sub potent drug: during the 9-month stability test conducted, the assay value for the affected lot was below specification limit.

  • FDAClass III

    Carton label: Testosterone Gel 1%

    Defective Container - A defect in the side-seal which allows leakage of product.

  • FDAClass II

    Sertraline Hydrochloride Tablets USP

    Defective container - seal not adhering to bottles

  • FDAClass II

    OraVerse

    Defective container: cracked/broken cartridges

  • FDAClass II

    Lidocaine HCI 2% and Epinephrine 1:100

    Defective container: cracked/broken cartridges

  • FDAClass II

    darby dental supply

    Defective container: cracked/broken cartridges

  • FDAClass II

    Cook-Walte

    Defective container: cracked/broken cartridges

  • FDAClass II

    Benco dental Graham CHEMICAL CO

    Defective container: cracked/broken cartridges

  • FDAClass II

    3% Polocaine DENTAL

    Defective container: cracked/broken cartridges

  • FDAClass II

    2% Xylocaine DENTAL with Epinephrine 1:100

    Defective container: cracked/broken cartridges

  • FDAClass II

    Phytonadione Injectable Emulsion, USP 10mg/mL, 10x1 mL Single-Dose Vial/carton, Rx Only, Mfd

    Failed Stability Specifications: Observed OOS results: eg results for colour index

  • FDAClass II

    WeCare, Zinc Oxide Ointment, Net Wt

    cGMP deviations

  • FDAClass II

    Wecare Enema

    cGMP deviations

  • FDAClass II

    Wecare Calasoothe, Net wt

    cGMP deviations

  • FDAClass II

    Nivagen Pharmaceuticals, Zinc Oxide Ointment USP, Zinc Oxide 20% Skin Protectant, Net Wt

    cGMP deviations

  • FDAClass II

    Nivagen, Zinc Oxide Ointment USP, Zinc Oxide 20 %, Net Wt

    cGMP deviations

  • FDAClass II

    Nivagen, Zinc Oxide Ointment, Net Wt

    cGMP deviations

  • FDAClass II

    Lanashield Skin Barrier, 4 oz

    cGMP deviations

  • FDAClass II

    Globe Zinc Oxide Ointment USP Zinc Oxide 20% Skin Protectant, Net Wt

    cGMP deviations

  • FDAClass II

    Globe Clotrimazole Cream USP, 1 % Antifungal Cream, Net Wt., 5 oz

    cGMP deviations

  • FDAClass II

    Globe Clotrimazole Cream, USP, 1 %, Net Wt

    cGMP deviations

  • FDAClass II

    Dynashield Skin Protectant, Net Wt

    cGMP deviations

  • FDAClass II

    Dynashield

    cGMP deviations

  • FDAClass II

    Dynagel, Moisturizing Wound Hydrogel, Net Wt

    cGMP deviations

  • FDAClass I

    POTASSIUM CHLORIDE Inj

    Labeling: Label Error on Declared Strength-The overwrap label may incorrectly identify the product as POTASSIUM CHLORIDE Inj. 10 mEq instead of POTASSIUM CHLORIDE Inj. 20 mEq

  • FDAClass I

    POTASSIUM CHLORIDE Inj

    Labeling: Label Error on Declared Strength-The overwrap label may incorrectly identify the product as POTASSIUM CHLORIDE Inj. 10 mEq instead of POTASSIUM CHLORIDE Inj. 20 mEq

  • FDAClass II

    Lanthanum Carbonate chewable tablets

    Failed stability specifications: Out of specification for hardness test

  • FDAClass II

    Lanthanum Carbonate chewable tablets

    Failed stability specifications: Out of specification for hardness test

  • FDAClass III

    Klarity-C Drops (Cyclosporine) 0.1%

    Subpotent Drug

  • FDAClass II

    Acetaminophen 500mg Caffeine 65mg caplets

    Labeling: Label Mix-up. This issue affects the outer box labeling only. The box incorrectly states the ingredients Acetaminophen 500mg and Caffeine 65mg. The inner pouch correctly states the ingredients are Aspirin (NSAID)*500mg and Caffeine 32.5mg.

  • FDAClass II

    Tirzepatide Injection

    Lack of Assurance of Sterility

  • FDAClass II

    Semaglutide Injection

    Lack of Assurance of Sterility

  • FDAClass II

    Semaglutide Injection

    Lack of Assurance of Sterility

  • FDAClass II

    Semaglutide Injection

    Lack of Assurance of Sterility

  • FDAClass II

    Semaglutide Injection

    Lack of Assurance of Sterility

  • FDAClass II

    Amoxicillin and Clavulanate Potassium for Oral Suspension USP

    Subpotent drug; Clavulanate Potassium component

  • FDAClass II

    HADLIMA (adalimumab-bwwd) injection

    Lack of Assurance of Sterility.

  • FDAClass II

    Haloperidol Lactate Injection

    Labeling: Not Elsewhere Classified:Incorrect RFID tag labels applied to product by repackaging firm.

  • FDAClass II

    Sugared+Bronzed Tinted Mineral Sunscreen SPF 50, Zinc Oxide 21%, Net WT 3.3 OZ (93 G) per tube, Dist

    CGMP Deviations

  • FDAClass II

    Sea Enzyme Ultra Umbrella Sunscreen SPF 30

    CGMP Deviations

  • FDAClass II

    Karina Daily Moisturizer SPF 25, Octinoxate 7.5% and Zinc Oxide 7.0%, Net WT

    CGMP Deviations

  • FDAClass II

    Gabriel Mineral Sunscreen SPF 50, Zinc Oxide 21%, 2.1 oz, Net 61 g per tube, Dist

    CGMP Deviations

  • FDAClass II

    Elixir by Coco March Tinted Mineral Sunscreen SPF 50

    CGMP Deviations

  • FDAClass II

    Elixir by Coco March Mineral Sunscreen SPF 50

    CGMP Deviations

  • FDAClass II

    Dr

    CGMP Deviations

  • FDAClass II

    Doctor

    CGMP Deviations

  • FDAClass II

    Doctor D

    CGMP Deviations

  • FDAClass II

    Doctor D

    CGMP Deviations

  • FDAClass II

    Doctor D

    CGMP Deviations

  • FDAClass II

    Doctor D

    CGMP Deviations

  • FDAClass II

    Doctor D

    CGMP Deviations

  • FDAClass II

    CLEARSTEM YOU ARE SUNSHINE SPF 50

    CGMP Deviations

  • CPSCCritical

    Dissolved Oxygen Test Kits

    The recalled test kits contain a bottle of sulfuric acid, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The test kits violate the mandatory standard for child-resistant packaging because the bottle of sulfuric acid is not child-resistant, posing a risk of serious injury or death from poisoning, if the contents are swallowed by young children.

  • CPSCCritical

    RELIEVE Numbing Cream

    The numbing cream contains lidocaine, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The numbing cream's packaging is not child-resistant, posing a risk of serious injury or death from poisoning, if the contents are swallowed by young children.

  • FDAClass II

    Fentanyl citrate

    CGMP Deviations: Revised interpretation of Acceptable Quality Level (AQL) results.

  • FDAClass II

    Phenylephrine HCI

    CGMP Deviations

  • FDAClass III

    Espumil, Lipophilic foam base, 500 ml, 24G15-T02-115604

    Labeling: Not Elsewhere Classified

  • CPSCInfo

    Bariatric Fusion Iron Multivitamin Bottles

    The recalled multivitamins contain iron, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The recalled packaging of the iron-containing multivitamins violates the federal standard for child-resistant packaging because the bottle caps are not child-resistant, posing a risk of deadly poisoning, if the contents are swallowed by young children.

  • CPSCCritical

    Séfralls Minoxidil Hair Generation Serum

    The hair serum contains minoxidil, which must be in child-resistant packaging as required by the Poison Prevention Packaging Act. The hair serum's packaging is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.

  • CPSCInfo

    California Gold Nutrition Iron Supplements: Daily Prenatal Multi, Ultamins Women's Multivitamin, and Ultamins Women's 50+ Multivitamin

    The recalled dietary supplements contain iron, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The iron-containing dietary supplement packages violate the federal standard for child-resistant packaging because the bottles and blister packs are not child-resistant, posing a risk of deadly poisoning, if the contents are swallowed by young children.

  • CPSCInfo

    Safetussin Max Strength Multi-Symptom Cough, Cold and Flu tablets blister packs

    The Safetussin over-the-counter cold medicine contains acetaminophen, which must be in child-resistant packaging as required by the Poison Prevention Packaging Act. The packaging of the products is not child-resistant as a tablet can be pushed through the foil, posing a risk of poisoning if the contents are swallowed by young children.

  • CPSCInfo

    NFH Iron SAP, NFH Heme Iron SAP and NFH Prenatal SAP bottles

    The recalled dietary supplements contain iron, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act (PPPA). The packaging is not child-resistant, posing a risk of poisoning if the contents are swallowed by young children.

  • CPSCInfo

    Benadryl Liquid Elixir, 100 mL bottles

    The Benadryl contains diphenhydramine, which must be in child-resistant packaging as required by the Poison Prevention Packaging Act. The packaging of the products is not child-resistant, posing a risk of poisoning if the contents are swallowed by young children.

2023 (2)

  • CPSCInfo

    Solaray Liposomal Multivitamins

    The recalled dietary supplements contain iron, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act (PPPA). The packaging of the products is not child-resistant, posing a risk of poisoning if the contents are swallowed by young children.

  • CPSCInfo

    Ferrous Sulfate (Iron) Enteric-Coated Tablets, 324 mg - 100 Tablet Bottles

    The recalled dietary supplements contain iron which must be in child-resistant packaging as required by the Poison Prevention Packaging Act (PPPA). The packaging of the products is not child-resistant, posing a risk of poisoning if the contents are swallowed by young children.

Independent news on labor, safety, and accountability.